Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: A matching-adjusted indirect comparison

被引：32

作者：

Signorovitch J. ^{[1
]}

Swallow E. ^{[1
]}

Kantor E. ^{[1
]}

Wang X. ^{[2
]}

Klimovsky J. ^{[2
]}

Haas T. ^{[3
]}

Devine B. ^{[4
]}

Metrakos P. ^{[5
]}

机构：

[1] Analysis Group Inc., 111 Huntington Ave 10th Floor, Boston

[2] Novartis Pharmaceuticals Corporation, 180 Park Ave, Bldg 105, Florham Park

[3] Novartis Oncology, Postfach, CH-4002, Basel

[4] School of Pharmacy, University of Washington, Box 357630, 1959 NE Pacific St, Seattle

[5] McGill University Health Center, Multi-Organ Transplant and Hepatopancreatobiliary Service, Royal Victoria Hospital, 687 Pine Ave West, Montréal

来源：

Experimental Hematology & Oncology | / 2卷 / 1期

关键词：

Cross-over; Everolimus; Indirect comparison; Pancreatic neuroendocrine tumors; Sunitinib;

D O I：

10.1186/2162-3619-2-32

中图分类号：

学科分类号：

摘要：

Background: Everolimus and sunitinib have been approved for the treatment advanced pancreatic neuroendocrine tumors, but have not been compared to each other in a randomized trial and have not demonstrated prolonged overall survival compared to placebo. This study aimed to indirectly compare overall and progression-free among everolimus, sunitinib and placebo across separate randomized trials.Methods: A matching adjusted indirect comparison was conducted in which individual patient data from the pivotal trial of everolimus (n = 410) were adjusted to match the inclusion criteria and average baseline characteristics reported for the pivotal trial of sunitinib (n = 171). Prior to matching, trial populations differed in baseline performance status and prior treatments. After matching, these and all other available baseline characteristics were balanced between trials.Results: Compared to the placebo arm in the sunitinib trial, everolimus was associated with significantly prolonged overall survival (HR = 0.61, 95% CI = 0.38-0.98, p = 0.042).Compared to sunitinib, everolimus was associated with similar progression-free (hazard ratio for death (HR) = 0.84, 95% CI = 0.46-1.53, p = 0.578) and overall survival (HR = 0.81, 95% CI = 0.49-1.31, p = 0.383).Conclusion: After adjusting for observed cross-trial differences, everolimus treatment was associated with longer overall survival than the placebo arm in the sunitinib trial for advanced pancreatic neuroendocrine tumors. © 2013 Signorovitch et al.; licensee BioMed Central Ltd.

引用

共 31 条

[1]

Yao, J.C., Hassan, M., Phan, A., Dagohoy, C., Leary, C., Mares, J.E., Abdalla, E.K., Evans, D.B., One hundred years after " carcinoid" : epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States (2008) J Clin Oncol, 26, pp. 3063-3072. , 10.1200/JCO.2007.15.4377, 18565894

[2]

Halfdanarson, T.R., Rabe, K.G., Rubin, J., Petersen, G.M., Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival (2008) Ann Oncol, 19, pp. 1727-1733. , 10.1093/annonc/mdn351, 2735065, 18515795

[3]

Kulke, M.H., Bendell, J., Kvols, L.K., Picus, J., Pommier, R., Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors (2011) J Hematol Oncol, 4, p. 29. , 10.1186/1756-8722-4-29, 3128039, 21672194

[4]

Rinke, A., Michl, P., Gress, T., Medical treatment of gastroenteropancreatic neuroendocrine tumors (2012) Cancers, 4, pp. 113-129. , 10.3390/cancers4010113, 3712673, 24213230

[5]

Yao, J.C., Phan, A.T., Chang, D.Z., Wolff, R.A., Hess, K., Gupta, S., Jacobs, C., Meric-Bernstam, F., Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study (2008) J Clin Oncol, 26, pp. 4311-4318. , 10.1200/JCO.2008.16.7858, 2653122, 18779618

[6]

Yao, J.C., Lombard-Bohas, C., Baudin, E., Kvols, L.K., Rougier, P., Ruszniewski, P., Hoosen, S., Lebwohl, D., Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial (2010) J Clin Oncol, 28, pp. 69-76. , 10.1200/JCO.2009.24.2669, 19933912

[7]

Faivre, S., Delbaldo, C., Vera, K., Robert, C., Lozahic, S., Lassau, N., Bello, C., Massimini, G., Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer (2006) J Clin Oncol, 24, pp. 25-35. , 10.1200/JCO.2005.02.2194, 16314617

[8]

Kulke, M.H., Lenz, H.J., Meropol, N.J., Posey, J., Ryan, D.P., Picus, J., Bergsland, E., Huang, X., Activity of sunitinib in patients with advanced neuroendocrine tumors (2008) J Clin Oncol, 26, pp. 3403-3410. , 10.1200/JCO.2007.15.9020, 18612155

[9]

Afinitor [package insert], , http://www.pharma.us.novartis.com/product/pi/pdf/afinitor.pdf

[10]

Sutent [package insert], , http://labeling.pfizer.com/ShowLabeling.aspx?id=607

← 1 2 3 4 →